• Most Popular
  • Most Shared

Acorda eager to develop other MS-related drugs

Mon Jun 2, 2008 2:55pm EDT

Stocks

   

NEW YORK, June 2 (Reuters) - The chief executive of Acorda Therapeutics Inc (ACOR.O) said approval of its most important drug could happen as soon as next year and transform the tiny biotech company, bringing in enough revenue to develop other highly promising medicines related to multiple sclerosis.

Stocks  |  Global Markets

Acorda said on Monday it plans to seek U.S. approval early next year for its lead medicine, called fampridine, after a second late-stage trial showed it could significantly increase walking ability in patients with multiple sclerosis.

Analysts estimate the drug, which helps mobility, but does not slow progression of the neurological disease, could garner peak annual global sales of up to $800 million. (Reporting by Ransdell Pierson; Editing by Andre Grenon)

Stocks
Global Markets


More from Reuters

Joint Terminal Attack Controller SSgt Clinton J. Herbison, a U.S. Airman from the 817 Expeditionary Air Support Operations Squadron (EASOS) takes a break during a night mission near Honaker Miracle camp at the Pesh valley of Kunar Province August 12, 2009. Credit: REUTERS/Carlos Barria

Pictures of the Year

A look at the best photos of 2009.  Slideshow 

    PICTURES
    The Dalai Lama jokes with a nasal spray after being asked his opinion on the swine flu during a press conference after his first lecture in Lausanne, Switzerland, August 4, 2009. REUTERS/ Valentin Flauraud

    What a wacky year it's been...

    Um, what's up the Dalai Lama's nose? "Oddly Enough" editor Bob Basler rounds up the goofiest photos of the year.  Full Article 

    Oddly Enough
    A caution sign is seen next to a stock board at the Australian Securities Exchange (ASX) in Sydney September 5, 2008. REUTERS/Daniel Munoz
    Political Risk in 2010:

    Don't say we didn't warn you

    With the financial crisis (mostly) in the past, U.S. investors are eying a fresh start to the coming year. Here's a look at what speedbumps lie ahead.  Full Article 

    Global Markets